Homology Medicines, Inc.

Homology Medicines is on a mission to advance our proprietary gene editing and gene therapy platform and transform the lives of patients by potentially curing rare genetic diseases.Our Company is based on an important scientific discovery – a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or by harnessing the body’s natural DNA repair process of homologous recombination through nuclease-free gene editing.

Bank Name Homology Medicines, Inc.
Stock Exchange NASDAQ
Symbol FIXX
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
CEO Dr. Arthur O. Tzianabos
Employees 70
Website www.homologymedicines.com
Registered Year 2015